Repository logo
 
Publication

Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease

2022-12Journal article Open access
Simple item page
dc.contributor.authorSilva, Inês
dc.contributor.authorEstarreja, João
dc.contributor.authorPinto, Rui
dc.contributor.authorMateus, Vanessa
dc.date.accessioned2022-12-07T15:36:31Z
dc.date.available2022-12-07T15:36:31Z
dc.date.issued2022-12
dc.descriptionFCT_UIDB/05608/2020. FCT_UIDP/05608/2020.pt_PT
dc.description.abstractBackground: Inflammatory Bowel Disease (IBD) is recognized as a group of chronic inflammatory disorders, localized in the gastrointestinal tract, which does not have a cure known. Indeed, the pharmacological approaches, commonly used, demonstrate significant toxicity, which highlights the need of investigating new possible treatments. Erythropoietin (EPO) is clinically used in anemic patients, with chronic renal insufficiency, due to its erythropoietic effect. However, it has also been described other non-erythropoietic effects, such as an anti-inflammatory role. There is already preclinical evidence about its anti-inflammatory effect in the IBD context, namely in an acute model of colitis in mice. Therefore, it is relevant to ascertain its anti-inflammatory effect in a chronic model, but mainly its hematopoietic side effect, during chronic treatment. Aim: This experiment aims to evaluate the efficacy and safety of EPO treatment in a chronic 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis model in rodents. Methods: The induction of chronic colitis consisted of five weekly intrarectal administrations of 1% TNBS, and then mice were treated daily with 500 IU/Kg or 1000 IU/Kg of EPO, through intraperitoneal injections, for 14 days. Results: EPO demonstrated a significant anti-inflammatory effect, translated by a significant reduction of the concentration of tumor necrosis factor-α, fecal calprotectin, and fecal hemoglobin. Moreover, it has also been demonstrated to be safe, considering the cardiovascular system, in terms of extraintestinal manifestations, namely at renal and hepatic functions. Conclusions: EPO demonstrated to be a promising pharmacological approach to be considered in the management of IBD, being an interesting target for drug repositioning.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSilva IJ, Estarreja J, Pinto R, Mateus V. Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease. Biomed Pharmacother. 2022;156:113944.pt_PT
dc.identifier.doi10.1016/j.biopha.2022.113944pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/15129
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0753332222013336pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectAnti-inflammatory effectpt_PT
dc.subjectDrug repositioningpt_PT
dc.subjectErythropoietinpt_PT
dc.subjectExperimental colitispt_PT
dc.subjectInflammatory bowel diseasept_PT
dc.subjectTNBS-induced colitispt_PT
dc.subjectFCT_UIDB/05608/2020pt_PT
dc.subjectFCT_UIDP/05608/2020pt_PT
dc.titleEfficacy and safety of erythropoietin in a chronic model of inflammatory bowel diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage113944pt_PT
oaire.citation.titleBiomedicine & Pharmacotherapypt_PT
oaire.citation.volume156pt_PT
person.familyNameda Silva
person.familyNameEstarreja
person.familyNamePinho Mateus
person.givenNameInês Filipa Janeiro da Silva
person.givenNameJoão
person.givenNameVanessa Alexandra
person.identifier.ciencia-idC010-323F-3266
person.identifier.ciencia-idEB19-EDA2-704B
person.identifier.ciencia-id5A12-571D-AD6A
person.identifier.orcid0000-0001-7049-2512
person.identifier.orcid0000-0002-8283-3174
person.identifier.orcid0000-0002-3204-3772
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication995e1831-ff5b-49e7-a6e3-8bc692212204
relation.isAuthorOfPublicationd16a20d0-ac73-4989-b83d-abeab53139f7
relation.isAuthorOfPublication406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscovery406041a5-682c-4f94-a4e2-ddbfc541313c

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease.pdf
Size:
1.86 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos